On the 8th, the Ministry of SMEs and Startups announced that it hosted the 'Korea-Japan Bio Cooperation Networking' event at the InterContinental Hotel in Seoul.
This event was organized as a follow-up to the 'Korea-Japan Bio Ecosystem Roundtable' held in Tokyo in February, aiming to strengthen business partnerships and expand cooperation opportunities between Korean bio venture corporations and Japanese global pharmaceutical companies.
The event was attended by over 50 industry stakeholders from both countries, including nine Korean bio venture corporations such as Atheon Bio and TC Nova Bioscience, and eight Japanese pharmaceutical companies including Eli Lilly Japan and Otsuka Pharmaceutical.
The event consisted of investment presentations (IR) from Korean bio venture corporations and networking sessions for business leaders from both countries. During the investment presentations, innovative drug development venture corporations introduced technologies such as artificial intelligence in immune oncology drug design, exploring collaboration possibilities with Japanese pharmaceutical companies.
Lim Jeong-wook, head of the Startup Venture Innovation Department at the Ministry of SMEs and Startups, noted, 'The biohealth industry is a key growth driver of the 21st century,' and added, 'If Korea and Japan leverage their respective strengths to pursue complementary cooperation, they can secure greater competitiveness in the global market.'